Impact of the matrix metalloproteinase MMP-3 on dementia
Abstract
Cerebral accumulation of β-amyloid peptide (Aβ) is a central event in the pathogenesis of Alzheimer's disease (AD). Several proteases were shown to hydrolyze Aβ in vitro or in cell-based assays, and are likely candidates for a role in Aβ clearance in brain. Previous reports suggest that matrix metalloproteinases (MMPs) could be involved in such a mechanism. A functional polymorphism at position −1171 (5A/6A) in MMP-3 was examined in two independent studies to investigate the impact of this polymorphism on the risk of developing dementia. We found that subjects APOE ɛ4 non-carriers and 6A/6A homozygous for the MMP-3 polymorphism were at increased risk of dementia. Our findings support the hypothesis that MMPs may influence the risk of dementia.
Keywords: Alzheimer's disease, Late-onset Alzheimer's disease, β-Amyloid peptide, Clearance, Matrix metalloproteinase, Genetic polymorphism, Genetic association study
To access this article, please choose from the options below
PII: S0197-4580(06)00189-8
doi:10.1016/j.neurobiolaging.2006.05.030
© 2006 Elsevier Inc. All rights reserved.
